No­var­tis of­fers glimpse at BTK in­hibitor plans be­yond lead in­di­ca­tions: #AAD24

No­var­tis pro­vid­ed a peek Sat­ur­day of how it might ex­pand de­vel­op­ment of its ex­per­i­men­tal drug remi­bru­ti­nib, a BTK in­hibitor be­ing test­ed in a range of im­munol­o­gy and neu­rol­o­gy con­di­tions.

In a plat­form tri­al ex­am­in­ing five com­pounds in the chron­ic skin con­di­tion hidradeni­tis sup­pu­ra­ti­va, remi­bru­ti­nib met its pri­ma­ry end­point at both dose lev­els. The da­ta are ear­ly, as on­ly 66 pa­tients re­ceived remi­bru­ti­nib, split even­ly be­tween the 25 mg and 100 mg dos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER